Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 3/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146970 | 0.87 | EPHX2 (0.50) | NPY2RCNR1CNR2TRPV1EPHX2 | |
| SCHEMBL1147339 | 0.87 | EPHX2 (0.44) | NPY2RCNR1CNR2SCDTRPV1 | |
| SCHEMBL1147124 | 0.86 | POLB (0.49) | TRPV1ALDH1A1 | |
| SCHEMBL1147359 | 0.85 | EPHX2 (0.52) | NPY2RCNR1CNR2TRPV1EPHX2 | |
| SCHEMBL15387528 | 0.85 | NPY2R (0.46) | NPY2RCNR1CNR2SCDTRPV1 | |
| SCHEMBL1147033 | 0.85 | EPHX2 (0.46) | NPY2RCNR1CNR2TRPV1EPHX2 | |
| SCHEMBL1146903 | 0.80 | KDM4E (0.48) | TRPV1ALDH1A1 | |
| SCHEMBL1147355 | 0.80 | CNR2 (0.61) | CNR1CNR2TRPV1EPHX2 | |
| SCHEMBL1147071 | 0.79 | EPHX2 (0.48) | NPY2RCNR1CNR2TRPV1EPHX2 | |
| SCHEMBL1147158 | 0.79 | EPHX2 (0.48) | NPY2RCNR1CNR2TRPV1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | claimed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | claimed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | ADRA1D, ADORA1, H1-0 | NPY2R 1038/4885CNR1 83/4885CNR2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.